Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
2(22%)
Results Posted
67%(4 trials)

Phase Distribution

Ph phase_2
1
11%
Ph phase_1
2
22%
Ph phase_3
4
44%
Ph phase_4
1
11%

Phase Distribution

2

Early Stage

1

Mid Stage

5

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
1(12.5%)
Phase 3Large-scale testing
4(50.0%)
Phase 4Post-market surveillance
1(12.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(6)
Other(1)

Detailed Status

Completed6
Recruiting2
unknown1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (25.0%)
Phase 21 (12.5%)
Phase 34 (50.0%)
Phase 41 (12.5%)

Trials by Status

completed667%
recruiting222%
unknown111%

Recent Activity

2 active trials
Showing 5 of 9
recruitingphase_2

Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

NCT05537896
recruitingphase_4

Therapeutic Options for CRAB

NCT06440304
unknown

Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection

NCT06223100
completedphase_3

Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections

NCT01978938
completedphase_3

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections

NCT01844856
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT05537896Phase 2

Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia

Recruiting
NCT06440304Phase 4

Therapeutic Options for CRAB

Recruiting
NCT06223100

Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection

Unknown
NCT01978938Phase 3

Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections

Completed
NCT01844856Phase 3

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Complicated Intra-abdominal Infections

Completed
NCT03032510Phase 3

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections

Completed
NCT02784704Phase 3

Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections

Completed
NCT02135302Phase 1

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With Impaired Hepatic Function and Healthy Subjects

Completed
NCT02135276Phase 1

A Phase 1, Open-Label Study to Assess the Single-Dose Pharmacokinetics of Eravacycline in Subjects With End Stage Renal Disease and Healthy Subjects

Completed

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9